삼진제약

005500KOSPI의약품 제조업

57.9 / 100

Reference Date: 2026-04-13

Financial Score27.0 / 40

News Sentiment12.9 / 25

Momentum8.0 / 20

Disclosure10.0 / 15

AI Analysis: PER is significantly undervalued vs. peers but Revenue metrics are weak. Roughly flat over the past month, and news sentiment is positive.

Company InformationBased on 2025 Annual Report

Business Overview

Samjin Pharmaceutical operates a diverse portfolio spanning OTC drugs, specialty pharmaceuticals, and APIs, leveraging its competitive edge in the pharmaceutical market. The company focuses on developing innovative treatments for age-related diseases and metabolic disorders, with key products including the anticoagulant 'Plaeris' and analgesic 'Geborin'. It is expanding into health foods and medical devices, and has enhanced its global production capabilities through the 2022 completion of its Osong facility.

Number of Employees

819people

Average Salary

81.5M KRW

Score Calculation Basis

Detailed Financial Score

PER

9.39Industry Average 14.806.5Point

Lower than industry avg (good)

PBR

0.85Industry Average 1.044.0Point

In line with industry avg

ROE

8.76Industry Average 4.425.5Point

2.0x industry avg (good)

Debt Ratio

11.36Industry Average 11.984.0Point

In line with industry avg

Trend 2023~20257.0 / 10 points

Revenue Growth Rate

1.0 / 3

Avg ▲2.9% (2-year basis)

Operating Profit Growth Rate

2.5 / 3

Avg ▲19.6% (2-year basis)

ROE Trend

3.5 / 4

Avg ROE 10.2% (improving, 3yr)

Detailed News Sentiment

19 totalPositive 5Neutral 8Negative 1Average Sentiment Score 52.1

Detailed Momentum

52-week position3.0Point

52w lower range (31%)

Current 18,440Won52-week high 21,10052-week low 17,240

1-month return3.0Point

1m 0.66% (flat)

Volume trend2.0Point

Volume decreasing

Detailed Disclosure

5 totalPositive 0Neutral 5Negative 0

Neutral사외이사의선임ㆍ해임또는중도퇴임에관한신고2026-03-24
Neutral정기주주총회결과2026-03-24
Neutral기업가치제고계획(자율공시) (2026년)2026-03-20
Neutral사업보고서 (2025.12)2026-03-16
Neutral감사보고서제출2026-03-16